SCHEMBL21982525

SCHEMBL21982525

CN1CCC2(CC1)Nc1ccc(OCC(N)=O)cc1N=C2N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ GRK2 P25098 1/20 0.35
▸ HSD17B10 Q99714 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ PDE3B Q13370 1/20 0.34
▸ PDE3A Q14432 1/20 0.34
▸ CHRM1 P11229 2/20 0.34
▸ LMNA P02545 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ TBXAS1 P24557 1/20 0.33
▸ PDK1 Q15118 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ PDK3 Q15120 1/20 0.33
▸ PDK4 Q16654 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ADORA2B P29275 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21982462 0.82 LMNA (0.35) KMT2AHSD17B10SMN1; SMN2LMNAOPRM1
SCHEMBL21982523 0.79 HTT (0.40) GAAADORA2AADORA2B
SCHEMBL21982527 0.75 PRKCB (0.31) —
SCHEMBL21982593 0.70 POLB (0.33) MEN1KMT2AHSD17B10SMN1; SMN2CHRM1
SCHEMBL11600967 0.62 MAOA (0.60) LCKPDE3BPDE3A
SCHEMBL31718406 0.62 MAOA (0.60) LCKPDE3BPDE3A
SCHEMBL17771704 0.61 PDK2 (0.43) MEN1KMT2AGRK2HSD17B10SMN1; SMN2
SCHEMBL10506137 0.60 MEN1 (0.58) MEN1KMT2ATBXAS1KDM4EALDH1A1
SCHEMBL18034967 0.59 SLC6A4 (0.41) MEN1KMT2AHSD17B10SMN1; SMN2TBXAS1
SCHEMBL7344872 0.59 MCL1 (0.49) MEN1KMT2AHSD17B10SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 LCK 2801/4885MEN1 3860/4885KMT2A 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback